Dare Bioscience Investor Presentation Deck
DARE-HRT1*
Combination bio-identical estradiol + bio-identical progesterone 28-day IVR for hormone therapy following menopause.
There are no FDA approved options with both hormones in one monthly IVR.
Over 45M women in U.S. approaching or in menopause¹
Hormone Therapy (HT)
HT remains the most effective treatment for vasomotor symptoms (VMS) and genitourinary syndrome of menopause (GSM), and has been
shown to prevent bone loss and fracture.²
•The 2022 Hormone Therapy Position Statement of The North American Menopause Society (NAMS), supports HT in peri-and post-
menopausal women.²
NAMS observes: non-oral routes may offer advantages over oral routes of administration.²
*505(b)(2) candidate3
1.U.S. Census Bureau, Population Division. Table 2. 2015 to 2060 (NP2012-T2). Released Dec. 2012,
https://media.bayer.com/baynews/baynews.nsf/id/6F1503CB434A4B10C1258742002736062open&ref=irrefndcd#text-The%20most%20frequently%20reported%20and.life's%20activity%2C%20personally%20and%20professionally.
2. https://www.menopause.org/docs/default-source/professional/nams-2022-hormone-therapy-position-statement.pdf
41View entire presentation